Powerful insights for successful outcomes
Tokenisation of patient data is well established in the commercial setting, but it is also applicable within clinical trials. It enables sponsors to link participant information in a blinded and encrypted way beyond the study setting, for better intelligence on health care outcomes and the development of more effective, safer drugs. Nonetheless, as with much evolution in the pharma industry, a lack of understanding around the concept could be a barrier to utilising its full potential.
What is Clinical Trial Tokenisation?
Hear the definitive explanation from the experts
A lack of understanding around the concept of clinical trial tokenisation could be a barrier to utilising its full potential. In this podcast we consider how tokenisation can be implemented into trials, challenges sponsors can prepare for and the benefits it can offer beyond the study itself.
Discover more about the use of real-word data and tokenisation in clinical trials in this informative podcast.
This video covers:
The fundamentals of Clinical Trial Tokenisation
Discover why pharmaceutical and biotech sponsors of all sizes should be considering adopting Clinical Trial Tokenisation as part of their product development strategy
Clinical Trial Tokenisation has the potential to provide valuable insight to inform strategic decisions on product development and commercialisation.
Access this thought leadership article from Scrip, in partnership with ICON, for the basic concept and considerations.
Uncovering the benefits of Clinical Trial Tokenisation
The decentralised clinical trials conversation is not complete without discussing real-world data and clinical trial tokenisation.
Hear from an industry expert on how sponsors will have the opportunity to gain more data to support regulatory submissions without additional burden to the patient or the investigator.
This video covers: